Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409627 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDHTTTSHRADRA2A | |
| SCHEMBL16214307 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDHTTTSHRADRA2A | |
| SCHEMBL17563496 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTTSHRPSMB8 | |
| SCHEMBL141048 | 0.87 | ADRA2A (0.36) | SMN1; SMN2ADRA2AADRA1APSMB8PSMB5 | |
| SCHEMBL13535883 | 0.87 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTTSHRPSMB8 | |
| SCHEMBL13535837 | 0.86 | HPGD (0.37) | SMN1; SMN2HPGDHTTTSHRADRA2A | |
| SCHEMBL12285234 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDHTTTSHRPSMB8 | |
| 2-Methoxyethanol SCHEMBL29386411 | 0.85 | HPGD (0.35) | SMN1; SMN2HPGDHTTADRA2AADRA1A | |
| SCHEMBL24564946 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDHTTTSHRPSMB8 | |
| SCHEMBL9329901 | 0.83 | DGKA (0.37) | HPGDTSHRADRA2AADRA1APSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172193-A1 | PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172193-A1 | PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | ARFGAP1, ABCC1, FPR1 | SMN1; SMN2 4475/4885HPGD 1559/4885HTT 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.